FDA concluded that NIH-funded BlueWillow Biologics (Ann Arbor, Mich.) had marketed an alcohol-free, over-the-counter (OTC) nasal antiseptic to “mitigate, prevent, treat, diagnose, or cure COVID-19 and other conditions in people.” The agency concluded that the NanoBio Protect product is an unapproved new drug and that the product is misbranded. FDA explained in the warning letter…